LabCorp® LH today announced it will participate at the 2018 Barclays Global Healthcare Conference. LabCorp's presentation is planned for Wednesday, March 14, 2018 at 9:30 am (ET).
A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.
About LabCorp
LabCorp LH, an S&P 500 company, is a
leading global life sciences company that is deeply integrated in
guiding patient care, providing comprehensive clinical laboratory and
end-to-end drug development services. With a mission to improve health
and improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology to
improve the delivery of care. LabCorp reported net revenues of over $10
billion in 2017. To learn more about LabCorp, visit www.labcorp.com,
and to learn more about Covance Drug Development, visit www.covance.com.
Forward-Looking Statements
This press release contains
forward-looking statements about the Company's future operations. Each
of the forward-looking statements is subject to change based on various
important factors, including without limitation, competitive actions in
the marketplace, and adverse actions of governmental and other
third-party payers. Actual results could differ materially from those
suggested by these forward-looking statements. The Company has no
obligation to provide any updates to these forward-looking statements
even if its expectations change. Further information on potential
factors that could affect operating and financial results is included in
the Company's Form 10-K for the year ended December 31, 2017, and
subsequent Forms 10-Q, including in each case under the heading risk
factors, and in the Company's other filings with the SEC. The
information in this press release should be read in conjunction with a
review of the Company's filings with the SEC including the information
in the Company's Form 10-K for the year ended December 31, 2017, and
subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180307006287/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
